Michigan Initial Experience Using Tigertriever for Thrombectomy

NCT07363525 | Not Yet Recruiting FDA Device

• 1 other identifier: 18750
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.

Conditions

Thrombectomy; Ischemic Stroke; Blood Clot

Keywords

thrombus; Clot; Device; Stroke

Outcome Measures

Primary Outcomes (3)

• Modified Rankin Scale

  Percentage of participants with a modified Rankin Scale (mRS) score ≤2

  From enrollment to 90 days post treatment

• Primary Effectiveness Endpoint

  Percentage of participants with a mTICI Score ≥IIb

  By the end of the thrombectomy procdure.

• Primary Effectiveness Endpoint - mTICI

  Percentage of participants with a mTICI Score ≥IIb after the first pass

  From time of event to after the first thrombectomy pass.

Study Arms (1)

Thrombectomy Treated Patients

Patients are enrolled only if the use of the Tigertreiver is used during surgery.

Procedure: Mechanical Thrombectomy

Interventions

Mechanical Thrombectomy PROCEDURE

You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.

Thrombectomy Treated Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The registry will include male or female subjects age \> 18 who present with LVO and are treated with the Tigertriever as per the approved indication.

You may qualify if:

• Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
• Tigertriever was used as the first line treatment in the target vessel.
• A signed informed consent.
• Age ≥ 18.

You may not qualify if:

• Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
• \. pre-stroke disability (pre-stroke mRS ≥ 2).

Sponsors & Collaborators

• Henry Ford Health System: lead

Study Sites (1)

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Location

MeSH Terms

Conditions

Thrombosis; Ischemic Stroke; Stroke

Condition Hierarchy (Ancestors)

Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Central Study Contacts

Alex Chebl, MD

CONTACT

313-916-2644; achebl1@hfhs.org

Kelly Tundo, RN

CONTACT

313-916-1102; kciach1@hfhs.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 90 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 8, 2026
• First Posted: January 23, 2026
• Study Start: January 15, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: January 23, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)